Arcus Biosciences, Inc. (RCUS) FY2025 10-K Annual Report
Arcus Biosciences, Inc. (RCUS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Arcus Biosciences, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of investigational pharmaceutical products in immuno-oncology
- • No new products or segments introduced; increased emphasis on regulatory, pricing, and healthcare reform risks in U.S. markets
- • Strategic risk focus shifted toward navigating U.S. drug pricing reforms and increased government healthcare cost containment measures
- • Significant stock ownership concentration with Gilead owning 25.1% and management owning 39.5% collectively as of December 31, 2025
- • Implementation of exclusive Delaware Court of Chancery forum for stockholder disputes to limit litigation venue options
Management Discussion & Analysis
- • No product sales revenue; all revenue from license, collaboration, and development services agreements
- • License and development services revenue recognized based on percentage completion of R&D obligations
- • R&D expenses include clinical, payroll, supplies, consulting, contract research; expect near-term R&D decrease due to winding down domvanalimab studies
- • Cash, cash equivalents, and marketable securities totaled $1.0 billion as of Dec 31, 2025, sufficient to fund operations until at least H2 2028
- • Management highlights risks and uncertainties; key focus on advancing casdatifan and inflammation programs with potential increased late-stage investment
Risk Factors
- • Regulatory risk from Gilead collaboration amendment causing revenue catch-up of $143M in 2025, impacting timing and recognition of license income
- • Macroeconomic exposure to collaboration funding variability, e.g., Taiho option revenue dropped from $15M in 2024 to $7M in 2025
- • Operational risk of impairment on right-of-use office assets due to 2024 updated space plans, reflecting changing facility requirements
- • Market disruption risk from Gilead's voluntary return of etrumadenant license, affecting Arcus's revenue and pipeline strategy
- • Financial risk from non-cash interest expenses related to liabilities under BVF royalty sale, impacting net income volatility
Arcus Biosciences, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$33M
▼ -35.3% YoY
Net Income
-$353M
▼ -24.7% YoY
Operating Margin
-1169.7%
▼ -52264bp YoY
Net Margin
-1069.7%
▼ -51480bp YoY
ROE
-55.9%
▲ +241bp YoY
Total Assets
$1.1B
▼ -1.0% YoY
EPS (Diluted)
$-3.29
▼ -4.8% YoY
Operating Cash Flow
-$482M
▼ -183.5% YoY
Source: XBRL data from Arcus Biosciences, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Arcus Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.